湖北科技学院学报（医学版）2026，Vol.40Issue(3)：208-211,4.DOI:10.16751/j.cnki.2095-4646.25111108
基于中国医院药物警戒系统的盐酸利托君注射液不良反应影响因素分析
Analysis of Influencing Factors for Adverse Reactions of Ritodrine Hydrochloride Injection Based on the Chinese Hospital Pharmacovigilance System
摘要
Abstract
Objective To utilize the Chinese Hospital Pharmacovigilance System(CHPS)to collect real-world data on adverse drug reactions(ADRs)associated with Ritodrine Hydrochloride Injection,analyze the influencing factors for ADR occurrence,and provide recom-mendations for rational clinical use.Methods Cases of patients who received Ritodrine Hydrochloride Injection at the First Affiliated Hospi-tal of Guangxi University of Science and Technology were collected via the CHPS.Based on the occurrence of ADRs,patients were divided into a study group and a control group.Univariate analysis and multivariate logistic regression were used to identify factors influencing ADRs.Results A total of 401 patients who received Ritodrine Hydrochloride Injection were included from the CHPS.ADRs occurred in 116 patients,yielding an ADR incidence rate of 28.93%.The main manifestations of ADRs involved cardiovascular system damage(41.26%),followed by metabolism and nutrition disorders(29.61%).Multivariate logistic regression analysis showed that BMI≤18.4kg/m2(OR=12.293,95%CI:1.474～30.537),duration of medication≥15 days(OR=3.433,95%CI:1.696～6.947),and placenta previa(OR=2.162,95%CI:1.100～4.247)were independent risk factors for ADR occurrence(P＜0.05).Conclusion During the clinical use of Rito-drine Hydrochloride Injection,close attention should be paid to pregnant women with low BMI,long-term medication use,and comorbid pla-centa previa.The risk of ADRs can be reduced through individualized dose adjustment and enhanced monitoring.关键词
利托君/药物不良反应/中国医院药物警戒系统/危险因素Key words
Ritodrine/Adverse drug reactions/Chinese Hospital Pharmacovigilance System/Risk factors分类
医药卫生引用本文复制引用
刘春丽,吴慧娴,韦翠薇,谭丽凤,黄秀云,廖玮..基于中国医院药物警戒系统的盐酸利托君注射液不良反应影响因素分析[J].湖北科技学院学报（医学版）,2026,40(3):208-211,4.基金项目
广西壮族自治区卫生健康委员会自筹经费科研课题(Z20210192) （Z20210192）
